27.02.2024 16:32:22
|
Capricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock Up
(RTTNews) - Biotechnology company, Capricor Therapeutics Inc. (CAPR), Tuesday announced that it had been granted an in-person Type-B meeting with the U.S. Food and Drug Administration regarding the commercial launch of CAP-1002.
The company stated that it plans to accelerate the process of Biologics License Application or BLA submission with this meeting.
Earlier, CAP-1002 drug had received Regenerative Medicine Advanced Therapy or RMAT, and orphan drug designations for the treatment of patients with Duchenne muscular dystrophy or DMD, which is a genetic disorder involving muscle weakness and degeneration.
Currently, Capricor's stock is trading at $4.3877, up 10.80 percent on the Nasdaq.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Capricor Therapeutics Inc Registered Shsmehr Nachrichten
12.11.24 |
Ausblick: Capricor Therapeutics präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Capricor Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Capricor Therapeutics Inc Registered Shs | 14,32 | 2,87% |
|